24/7 Market News Snapshot 13 August, 2025 – ImmunityBio, Inc. Common Stock (NASDAQ:IBRX)

August 13, 2025

DENVER, Colo., 13 August, 2025 (www.247marketnews.com) – (NASDAQ:IBRX) are discussed in this article.
ImmunityBio, Inc. (IBRX) has demonstrated a significant upward trajectory in its stock performance, opening at $2.63 and trading as high as $2.855, reflecting an increase of approximately 15.59% from the prior session’s close of $2.470. The trading volume has reached 14.14 million shares, signaling heightened investor interest and potential shifts in market sentiment. Key technical levels to observe include resistance at around $2.90 and support near $2.60, making ongoing analysis of trading patterns and volume essential for assessing the viability of this rally.

Complementing this favorable market performance, ImmunityBio has announced promising preliminary results from its QUILT-106 Phase I clinical trial, which investigates the safety and efficacy of its innovative CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy for late-stage Waldenstrom macroglobulinemia (WM). This trial is pivotal for patients with relapsed or refractory B-cell lymphoma, aiming to offer a groundbreaking treatment option without the burden of chemotherapy.

In the trial, two heavily pretreated patients have achieved complete responses—one through the novel therapy alone and the other in combination with the monoclonal antibody rituximab—both maintaining remission for six months thus far. The outpatients experienced no significant toxicities, highlighting the treatment’s tolerability.

Led by Dr. Glenda Gray, the open-label study has enrolled 13 patients, including three diagnosed with WM, and the findings are set for presentation at the upcoming American Society of Hematology annual meeting. Dr. Jackie Thomson from Wits University expressed optimism about these results, viewing them as a potential turning point for treatment strategies in this rare lymphoma. With ongoing enrollment in the clinical trial, ImmunityBio aims to validate these early outcomes and expand its innovative approaches to cancer therapeutics.

Related news for (IBRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.